BRPI0416968A - formas sólidas de anticorpos anti-egfr - Google Patents

formas sólidas de anticorpos anti-egfr

Info

Publication number
BRPI0416968A
BRPI0416968A BRPI0416968-9A BRPI0416968A BRPI0416968A BR PI0416968 A BRPI0416968 A BR PI0416968A BR PI0416968 A BRPI0416968 A BR PI0416968A BR PI0416968 A BRPI0416968 A BR PI0416968A
Authority
BR
Brazil
Prior art keywords
antibody
egfr antibodies
present
solid forms
solid
Prior art date
Application number
BRPI0416968-9A
Other languages
English (en)
Inventor
Susanne Matheus
Hanns-Christian Mahler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34625406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0416968A publication Critical patent/BRPI0416968A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"FORMAS SóLIDAS DE ANTICORPOS ANTI-EGFR". A presente invenção refere-se a formas sólidas de anticorpos contra o receptor EGF, particularmente precipitados e cristais de anticorpos monoclonais contra o receptor EGF, particularmente preferivelmente de Mab C225 (cetuximab) e Mab h425 (EMD 72000), que resulta na proteína de anticorpo biologicamente ativa através da dissolução ou suspensão em meio aquoso, obtenível pela precipitação do anticorpo e/ou de suas variantes e/ou fragmentos dissolvidos ou suspensos em meio aquoso por intermédio de um reagente de precipitação. A presente invenção também se refere a preparações farmacêuticas compreendendo pelo menos uma forma sólida dos anticorpos acima mencionados na forma de precipitado não-cistalino, precipitado cristalino ou na forma solúvel ou suspensa, e opcionalmente excipientes e/ou adjuvantes e/ou ingredientes farmacêuticos ativos adicionais, e a um processo para a preparação de formas sólidas de anticorpos anti-EGFR de acordo com a presente invenção.
BRPI0416968-9A 2003-11-29 2004-11-12 formas sólidas de anticorpos anti-egfr BRPI0416968A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10355904A DE10355904A1 (de) 2003-11-29 2003-11-29 Feste Formen von anti-EGFR-Antikörpern
PCT/EP2004/012837 WO2005051355A1 (de) 2003-11-29 2004-11-12 Feste formen von anti-egfr-antikörpern

Publications (1)

Publication Number Publication Date
BRPI0416968A true BRPI0416968A (pt) 2007-02-21

Family

ID=34625406

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416968-9A BRPI0416968A (pt) 2003-11-29 2004-11-12 formas sólidas de anticorpos anti-egfr

Country Status (21)

Country Link
US (1) US7960516B2 (pt)
EP (2) EP1686961A1 (pt)
KR (2) KR20120093406A (pt)
CN (1) CN1886118A (pt)
AR (1) AR046677A1 (pt)
AU (1) AU2004292742B9 (pt)
BR (1) BRPI0416968A (pt)
CA (1) CA2547446C (pt)
CO (1) CO5690537A2 (pt)
DE (1) DE10355904A1 (pt)
EC (1) ECSP066681A (pt)
IL (1) IL175935A (pt)
MX (1) MXPA06005968A (pt)
MY (1) MY148228A (pt)
NZ (1) NZ548210A (pt)
PE (1) PE20050667A1 (pt)
RU (1) RU2397755C2 (pt)
TW (1) TWI350291B (pt)
UA (1) UA84893C2 (pt)
WO (1) WO2005051355A1 (pt)
ZA (1) ZA200605348B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP2042194A3 (en) * 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2005090407A1 (en) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
EP1753404A1 (en) * 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
CA2566079A1 (en) * 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
NZ613356A (en) 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
CA2682135A1 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
EP2212412A4 (en) * 2007-10-15 2011-03-09 Biogen Idec Inc METHODS OF MANUFACTURING A BIOLOGICAL PRODUCT USING AN INTERMEDIATE STABLE STORAGE PRODUCT
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102153648B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l4-h3及其编码基因与应用
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
ES2762672T3 (es) 2014-02-19 2020-05-25 Bioasis Technologies Inc Proteínas de fusión de P97-IDS
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
PL3228650T3 (pl) * 2014-12-04 2022-06-27 Delta-Fly Pharma, Inc. Nowa pochodna PEG
AU2016218840A1 (en) * 2015-02-15 2017-08-31 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof
CN106999606B (zh) * 2015-02-17 2020-06-19 上海美雅珂生物技术有限责任公司 抗体药物偶联物
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
CN116063502A (zh) * 2015-06-30 2023-05-05 西雅图基因公司 抗ntb-a抗体和相关组合物以及方法
CN105810072A (zh) * 2016-03-25 2016-07-27 淮海工学院 一种蛋白质结晶的教学试剂盒及其方法
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
KR20210033470A (ko) * 2018-06-18 2021-03-26 바이엘 악티엔게젤샤프트 효소에 의해 절단 가능한 링커 및 개선된 활성 프로파일을 갖는, cxcr5에 대해 유도된 결합제-약물 접합체
JP7507145B2 (ja) 2018-08-13 2024-06-27 ベイジン パーカンズ オンコロジー カンパニー リミテッド 癌治療のためのバイオマーカー
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
TW202114738A (zh) * 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
US12485181B2 (en) * 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
CN119792564A (zh) * 2020-08-13 2025-04-11 正大天晴药业集团股份有限公司 抗体药物偶联物
CN114099422A (zh) * 2020-08-25 2022-03-01 泰州迈博太科药业有限公司 一种重组抗egfr单抗前体的制剂
US12178880B2 (en) * 2020-12-04 2024-12-31 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
CN115073437B (zh) * 2021-03-11 2023-07-18 北京师范大学 基于二氰基吡喃的大环多胺[12]aneN3化合物及其制备方法与用途
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
SK281143B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0586002T3 (da) 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
KR20100031769A (ko) * 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof

Also Published As

Publication number Publication date
IL175935A0 (en) 2006-10-05
CO5690537A2 (es) 2006-10-31
WO2005051355A1 (de) 2005-06-09
RU2397755C2 (ru) 2010-08-27
TWI350291B (en) 2011-10-11
KR20060111539A (ko) 2006-10-27
CN1886118A (zh) 2006-12-27
DE10355904A1 (de) 2005-06-30
AR046677A1 (es) 2005-12-14
UA84893C2 (en) 2008-12-10
US20070122411A1 (en) 2007-05-31
NZ548210A (en) 2010-10-29
AU2004292742B2 (en) 2011-08-25
CA2547446C (en) 2013-05-14
EP1974723A2 (de) 2008-10-01
ECSP066681A (es) 2006-10-25
CA2547446A1 (en) 2005-06-09
EP1974723A3 (de) 2010-06-09
ZA200605348B (en) 2007-04-25
RU2006123005A (ru) 2008-01-20
EP1686961A1 (de) 2006-08-09
AU2004292742A1 (en) 2005-06-09
TW200530268A (en) 2005-09-16
IL175935A (en) 2013-10-31
AU2004292742B9 (en) 2011-11-24
US7960516B2 (en) 2011-06-14
PE20050667A1 (es) 2005-09-27
KR20120093406A (ko) 2012-08-22
MY148228A (en) 2013-03-29
MXPA06005968A (es) 2006-07-06

Similar Documents

Publication Publication Date Title
UA84893C2 (en) Crystal form of monoclonal antibodies against the egf receptor - mab с225 and mab h425 (emd 72000)
CY1110700T1 (el) Ανασυνδυασμενα αντισωματα αντι-cd30 και χρησεις αυτων
JP2020007352A (ja) 血液脳関門シャトル
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
KR20250061718A (ko) 항-인플루엔자 b 바이러스 항체, 인플루엔자 b 바이러스의 검출용 시약 및 키트
CN108925136A (zh) 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
HRP20120893T1 (hr) Formulacija protutijela na histidin-acetatnom puferu
BR0211723A (pt) Bactérias corineformes que produzem compostos quìmicos i
BRPI0619357B8 (pt) anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
NO20052242L (no) Noytraliserende antistoffer mot GDF-8 og deres anvendelse.
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
BG111652A (en) Antibodies against the receptor of insulin-like growth factor i
BRPI0412245A (pt) anticorpos de rg1 e usos destes
BR0317896A (pt) Complexos de cristais de proteìna e polìmeros iÈnicos
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
PE20050586A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr
JP2008515775A5 (pt)
Kitajima et al. Differential distribution of spicule matrix proteins in the sea urchin embryo skeleton
IL276911B1 (en) Variants of the carboxylation rate of antibodies
BRPI0203949B8 (pt) polipeptídeo se36, processo para purificação do polipeptídeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
DK1165615T3 (da) Monoklonale antistoffer mod humant protein Mcm3, proces til deres fremstilling af deres anvendelse
ES2139568T3 (es) Complejo proteico.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014.